推荐产品
等级
pharmaceutical primary standard
API类
prazosin
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
Cl.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)c4ccco4
InChI
1S/C19H21N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22);1H
InChI key
WFXFYZULCQKPIP-UHFFFAOYSA-N
基因信息
human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)
正在寻找类似产品? 访问 产品对比指南
一般描述
Prazosin hydrochloride is an alpha-adrenergic blocking agent, employed as an antihypertensive drug for the treatment of high blood pressure. It lowers the blood pressure by binding to the alpha receptors thereby relaxing the blood vessels.
应用
It was used as an α1-adrenergic receptors antagonist, in a study performed to understand the influence of dopamine on uterine motility of rats in vitro.
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险声明
危险分类
Repr. 2 - STOT RE 2 - STOT SE 3
靶器官
Respiratory system
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Quantitative analysis of prazosin hydrochloride in pharmaceutical formulation by prazosin potentiometric sensor based on computational investigation.
Faridbod, Farnoush, et al.
International Journal of Electrochemical Science, 5, 653-667 (2010)
Physiologic evaluation of a new antihypertensive agent: prazosin HCl.
Koshy MC
Circulation, 55(3), 533-537 (1977)
Influence of dopamine on rat uterine motility in vitro.
Czerski, A., et al.
Acta Veterinaria Brno, 74.1, 9-15 (2005)
Guyoung Kwon et al.
Life sciences, 101(1-2), 73-78 (2014-03-04)
Danshensu [3-(3,4-dihydroxyphenyl)-lactic acid], a phenylpropanoid compound isolated from Prunella vulgaris var. lilacina, is a well-known antioxidant. Although its antioxidant activity and cardioprotective effect have been reported, the pharmacological properties of danshensu in the central nervous system remain unclear. We investigated
Renny Abraham et al.
Canadian journal of physiology and pharmacology, 93(1), 13-21 (2014-11-28)
An extensive amount of research has focused on the development of new pharmacological agents to treat schizophrenia. Varying from person to person, schizophrenia is a heterogeneous disease with symptoms of positive, negative, and cognitive deficits. PRX-07034, a 5-hydroxytryptamine6 (5-HT6) receptor
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门